Dyne Therapeutics is pioneering targeted therapies for patients with serious muscle diseases. Led by experts in therapeutic discovery and clinical development, Dyne is creating antibody conjugates that deliver medicine to the site of disease, a unique approach with the potential to restore muscle strength and transform the lives of patients and their families. Dyne was launched in 2019.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/03/19 | $50,000,000 | Series A |
Atlas Venture Forbion Capital Partners MPM Capital | undisclosed |
| 08/10/20 | $115,000,000 |
Atlas Venture Forbion Capital Partners Franklin Templeton Logos Capital MPM Capital Surveyor Capital  Vida Ventures Wellington Management Company | undisclosed |
